Top

Journal of Diabetes & Metabolic Disorders

Published in:

Open Access 01-12-2012 | Research article

The association of carotid intima media thickness with retinol binding protein-4 and total and high molecular weight adiponectin in type 2 diabetic patients

Authors: Masoumeh Mansouri, Ramin Heshmat, Ozra Tabatabaei-Malazy, Farshad Sharifi, Zohreh Badamchizadeh, Sudabeh Alatab, Kobra Omidfar, Hossein Fakhrzadeh, Bagher Larijani

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2012

Abstract

Background

The aim of this study was to investigate whether carotid intima media thickness (CIMT) is associated with serum level of retinol- binding protein-4 (RBP4) and total and high molecular weight (HMW) adiponectin in type 2 diabetes (T2DM) without clinical symptom of atherosclerotic disease.

Method

101 type 2 diabetic patients (mean age, 53.63 ± 8.42 years) and 42 body mass index (BMI) matched control (mean age 50.1 ± 8.4) were recruited. The CIMT was assessed by using B-mode ultrasonography, while serum levels of RBP4 and total and HMW adiponectin were measured by using enzyme linked immunosorbant assay (ELISA). Linear regression analysis was performed with CIMT as dependent variable and adipokines and cardio metabolic risk factors as independent variables.

Result

The CIMT was higher in diabetic group compared to control group (p <0.05). The mean concentration of RBP4 and total and HMW adiponectin did not differ between two groups.

Age (B = 0.44 P <0.05), blood pressure (B = 0.37 P = <0.05), waist circumference (B = −0.21 P <0.05) and TG (B = 0.1 P <0.05) were identified as independent predictors for CIMT in diabetic group, while RBP4 and adiponectin were not associated with CIMT neither in diabetic group nor in control group.

Conclusion

In conclusion, the present study showed that serum levels of RBP4 or total and HMW adiponectin were not potential predictors of CIMT in type 2 diabetic patients who exposed to this risk factor at least for nine years.

Available only for authorised users

Wacker FJ, Yaung LH, Inzucchi SH, et al.: Detection of silent myocardial Ischemia in asymptomatic diabetic subjects. Diabetes Care 2004, 27: 1954–1961. https://doi.org/10.2337/diacare.27.8.1954CrossRef

Stehouwer CD, Henry RM, Ferreria I: Arterial stiffness in diabetes and the metabolic syndrome a pathway to cardiovascular disease. Diabetologia 2008, 51: 527–539. https://doi.org/10.1007/s00125-007-0918-3CrossRef

Thanh HT, Benzaquen BS: Screening for subclinical coronary artery disease measuring carotid intima media thickness. Am J Cardio 2009, 104: 1383–1388. https://doi.org/10.1016/j.amjcard.2009.07.005CrossRef

Djaberi R, Schuijf JD, Jukema JW, et al.: Increased carotid intima-media thickness as a predictor of the presence and extent of abnormal myocardial perfusion in type 2 diabetes. Diabetes Care 2010, 33(2):372–374. https://doi.org/10.2337/dc09-1301CrossRef

Esteve E, Ricart W, Fernandez-Real JM, Adipocytokines and insulin resistance. The possible role of lipocalin-2, retinol binding protein-4, and insulin resistance: Adipocytokines and insulin resistance. The possible role of lipocalin-2, retinol binding protein-4, and insulin resistance. Diabetes Care 2009, 32(Supplement 2):S362-S367.CrossRef

Rabe K, Lehrke M, Parhofer KG, et al.: Adipocytokines and insulin resistance. Mol Med 2008, 14(11–12):741–751.CrossRef

Rasouli N, Kern PA: Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008, 93(11):564–573.

Beauloye V, Zech F, Mong HTT, et al.: Determinants of early Atherosclerosis in obese children and adolescents. J Clin Endocrinol Metab 2007, 92(8):3025–3032. https://doi.org/10.1210/jc.2007-0619CrossRef

Hutley L, Prins B: Fat as endocrine organ: relationship to the metabolic Syndrome. Am J Med Sci 2005, 330: 280–289. https://doi.org/10.1097/00000441-200512000-00005CrossRef

10.

Hassink S, Balagopal PB: RBP4: from retinol transporter to biomarker. J Pediatr 2009, 154: 5–7. https://doi.org/10.1016/j.jpeds.2008.08.024CrossRef

11.

Graham TE, Yang Q, Blüher M, et al.: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006, 354: 2552–2563. https://doi.org/10.1056/NEJMoa054862CrossRef

12.

Balagopal P, Graham TE, Kahn BB, et al.: Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab 2007, 92(5):1971–1974. https://doi.org/10.1210/jc.2006-2712CrossRef

13.

Maghbooli Z, Hossein-Nezhad A, Mirzaei K, et al.: Association between retinol-binding protein 4 concentrations and gestational diabetes mellitus and risk of developing metabolic syndrome after pregnancy. Reprod Sci 2010, 17(2):196–201. https://doi.org/10.1177/1933719109351097CrossRef

14.

Shimada K, Miyazaki T, Daida H: Adiponectin and atherosclerotic disease. Clin Chim Acta 2004, 344: 1–12. https://doi.org/10.1016/j.cccn.2004.02.020CrossRef

15.

Hotta K, Funahashi T, Arita Y, et al.: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler ThrombVasc Bio 2000, l20: 1595–1599. 159CrossRef

16.

Mansouri M, Keshtkar A, Hasani-Ranjbar S, et al.: The impact of one session resistance exercise on Plasm adiponectin and RBP4 concentration in trained and untrained healthy young men. Endocrin J 2011, 58(10):861–868. https://doi.org/10.1507/endocrj.EJ11-0046CrossRef

17.

Greenland p, Abrams J, Aurigemma GP: Prevention conference: beyond secondary prevention: Identifying the high-risk patient for primary prevention: non invasive tests of atherosclerotic burden. Circulation 2000, 101: E16-E22. https://doi.org/10.1161/01.CIR.101.1.e16CrossRef

18.

Levey AS, Bosch JP, Lewis JB, et al.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130: 461–470.CrossRef

19.

Shin JB, Seong YJ, Lee HJ, et al.: Foot Screening Technique in a Diabetic Population. J Korean Med Sci 2000, 15: 78–82.CrossRef

20.

Szmitko PE, Teoh H, Stewart DJ, et al.: Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol 2007, 292: 1655–1663.CrossRef

21.

Lo J, Dolan SE, Kanter JR, et al.: Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women. J Clin Endocrinol Metab 2006, 91: 1677–1682. https://doi.org/10.1210/jc.2005-2775CrossRef

22.

Pilz S, Horejsi R, Moller R, et al.: Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J Clin Endocrinol Metab 2005, 90: 4792–4796. https://doi.org/10.1210/jc.2005-0167CrossRef

23.

Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B: Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery Atherosclerosis. Stroke 2005, 36: 2577–2582. https://doi.org/10.1161/01.STR.0000190834.00284.fdCrossRef

24.

Mangge H, Almer1 G, Haj-Yahya1 S, et al.: Pre atherosclerosis and adiponectin subfractions in obese adolescents. Obesity 2008, 16(12):2578–2584. https://doi.org/10.1038/oby.2008.439CrossRef

25.

Norata GD, Raseli S, Grigore L, et al.: Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke 2007, 38: 2844. https://doi.org/10.1161/STROKEAHA.107.485540CrossRef

26.

Nilsson PM, Engström G, Hedblad B, et al.: Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 2006, 26: 2758–2762. https://doi.org/10.1161/01.ATV.0000249638.01416.4bCrossRef

27.

Ingelsson E, Lind L: Circulating retinol-binding protein 4 and subclinical cardiovascular disease in the. elderly. Diabetes Care 2009, 32: 733–735. https://doi.org/10.2337/dc08-1656CrossRef

28.

Takebayashi K, Suetsugu M, Wakabayashi S, et al.: Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007, 92: 2712–2719. https://doi.org/10.1210/jc.2006-1249CrossRef

29.

Park SE, Kim DH, Lee JH, et al.: Retinol-binding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis 2009, 204: 23–25. https://doi.org/10.1016/j.atherosclerosis.2008.08.012CrossRef

30.

Behrendt D, Gans p: Endothelial function. from vascular biology to clinical applications. Am J Cardiol 2002, 90: 40L-48L. https://doi.org/10.1016/S0002-9149(02)02963-6CrossRef

31.

Crous J: Predictive value of carotid 2-dimensionalultrasound. Am J Cardiol 2001, 88: 27–30. https://doi.org/10.1016/S0002-9149(01)01754-4CrossRef

32.

Wang Z, Nakayama T: Inflammation, a Link between Obesity and Cardiovascular Disease. Mediat Inflamm 2010, 2010: 535918.CrossRef

33.

Szmitko PE, Wang CH, Weisel RD, et al.: New markers of inflammation and endothelial cell activation. Circulation 2003, 108: 1917–1923. https://doi.org/10.1161/01.CIR.0000089190.95415.9FCrossRef

34.

Verma S, Anderson TJ: Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002, 105: 546–549. https://doi.org/10.1161/hc0502.104540CrossRef

35.

Chen H, Montagnani M, Funahashi T, et al.: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278: 45021–45026. https://doi.org/10.1074/jbc.M307878200CrossRef

36.

Iglseder B, Mackevics V, Stadlmayer A, et al.: Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis. Stroke 2005, 36: 2577–2582. https://doi.org/10.1161/01.STR.0000190834.00284.fdCrossRef

37.

Steinberg HO, Chaker H, Leaming R, et al.: Obesity/insulin resistance is associated with endothelial dysfunction implication for the syndrome of insulin resistance. J Clin Invest 1996, 97: 2601–2610. https://doi.org/10.1172/JCI118709CrossRef

38.

Kobashi C, Urakaze M, Kishida M, et al.: Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005, 97: 1245–1252. https://doi.org/10.1161/01.RES.0000194328.57164.36CrossRef

39.

Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100: 2473–2476. https://doi.org/10.1161/01.CIR.100.25.2473CrossRef

40.

Kuboki K, Jiang ZY, Takahara N, et al.: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000, 101: 676–681. https://doi.org/10.1161/01.CIR.101.6.676CrossRef

41.

Peppa-P M, Scordili M, Antoniou A, et al.: Carotid atherosclerosis in adolescents and young adults with IDDM. Relation to urinary endothelin, albumin, free cortisol, and other factors. Diabetes Care 1998, 21(6):1004–1007. https://doi.org/10.2337/diacare.21.6.1004CrossRef

Title: The association of carotid intima media thickness with retinol binding protein-4 and total and high molecular weight adiponectin in type 2 diabetic patients
Authors: Masoumeh Mansouri
Ramin Heshmat
Ozra Tabatabaei-Malazy
Farshad Sharifi
Zohreh Badamchizadeh
Sudabeh Alatab
Kobra Omidfar
Hossein Fakhrzadeh
Bagher Larijani
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Diabetes & Metabolic Disorders / Issue 1/2012
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1186/2251-6581-11-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Vitamin D status and associated factors in recent-onset type 1 diabetic children in Iran

The relationship between the activates of antioxidant enzymes in red blood cells and body mass index in Iranian type 2 diabetes and healthy subjects

Nurses’ role in diabetic foot prevention and care; a review

Diabetes and tuberculosis: a review of the role of optimal glycemic control

The care process of diabetic foot ulcer patients: a qualitative study in Iran

Development of an effective risk management system in a teaching hospital

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials